Marker Therapeutics, Inc. (MRKR) is a late-stage cancer therapeutics company specialized in the production of T cell-based immunotherapeutics for treating oncological issues. The company’s lead
On January 19, Marker Therapeutics Inc. (MRKR) announced FDA Orphan Drug designation for its pancreatic cancer T-cell therapy. Following the announcement, the stock became bullish
The stock of Marker Therapeutics plunged today by -4.26% to the current price of $1.80. The MRKR stock previously closed at $1.88. Marker Therapeutics Inc.
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.